Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

Di Giovanni G, De Deurwaerdère P.

Pharmacol Ther. 2016 Jan;157:125-62. doi: 10.1016/j.pharmthera.2015.11.009. Epub 2015 Nov 23. Review.

PMID:
26617215
2.

A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Palacios JM, Pazos A, Hoyer D.

Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418. doi: 10.1007/s00213-017-4545-5. Epub 2017 Mar 7. Review.

PMID:
28265714
3.

Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

De Deurwaerdère P, Lagière M, Bosc M, Navailles S.

Exp Brain Res. 2013 Oct;230(4):477-511. doi: 10.1007/s00221-013-3508-2. Epub 2013 Apr 25. Review.

PMID:
23615975
4.

5-HT2C receptors in psychiatric disorders: A review.

Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Apr 3;66:120-35. doi: 10.1016/j.pnpbp.2015.12.006. Epub 2015 Dec 29. Review.

PMID:
26739950
5.

We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.

Cheng J, Kozikowski AP.

ChemMedChem. 2015 Dec;10(12):1963-7. doi: 10.1002/cmdc.201500437. Epub 2015 Oct 28.

6.

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, Spampinato U.

J Neurosci. 2004 Mar 31;24(13):3235-41.

7.

Central serotonin2C receptor: from physiology to pathology.

Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E.

Curr Top Med Chem. 2006;6(18):1909-25. Review.

PMID:
17017966
8.

Serotonin/dopamine interaction--focus on 5-HT2C receptor, a new target of psychotropic drugs.

Di Giovanni G, Di Matteo V, Esposito E.

Indian J Exp Biol. 2002 Dec;40(12):1344-52. Review.

PMID:
12974395
9.

5-HT2C receptor modulators: a patent survey.

Lee J, Jung ME, Lee J.

Expert Opin Ther Pat. 2010 Nov;20(11):1429-55. doi: 10.1517/13543776.2010.518956. Epub 2010 Sep 17. Review.

PMID:
20849206
10.

5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence.

Martin CB, Martin VS, Trigo JM, Chevarin C, Maldonado R, Fink LH, Cunningham KA, Hamon M, Lanfumey L, Mongeau R.

Int J Neuropsychopharmacol. 2014 Oct 31;18(3). pii: pyu056. doi: 10.1093/ijnp/pyu056.

11.

Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice.

Moya PR, Fox MA, Jensen CL, Laporte JL, French HT, Wendland JR, Murphy DL.

BMC Pharmacol. 2011 Apr 7;11:3. doi: 10.1186/1471-2210-11-3.

12.

Studies on the neuroendocrine role of serotonin.

Jørgensen HS.

Dan Med Bull. 2007 Nov;54(4):266-88. Review.

PMID:
18208678
13.

Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications.

Berg KA, Clarke WP, Cunningham KA, Spampinato U.

Neuropharmacology. 2008 Nov;55(6):969-76. doi: 10.1016/j.neuropharm.2008.06.014. Epub 2008 Jun 17. Review.

14.

Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.

Nikiforuk A.

CNS Drugs. 2015 Apr;29(4):265-75. doi: 10.1007/s40263-015-0236-0. Review.

15.

Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB.

Pharmacol Ther. 2011 Feb;129(2):120-48. doi: 10.1016/j.pharmthera.2010.08.013. Epub 2010 Oct 20. Review.

16.

Serotonin2c receptor constitutive activity: in vivo direct and indirect evidence and functional significance.

Navailles S, Lagière M, Guthrie M, De Deurwaerdère P.

Cent Nerv Syst Agents Med Chem. 2013 Jun;13(2):98-107. Review.

PMID:
23441866
17.

Role of 5-HT(2C) receptors in the control of central dopamine function.

Di Matteo V, De Blasi A, Di Giulio C, Esposito E.

Trends Pharmacol Sci. 2001 May;22(5):229-32. Review.

PMID:
11339973
18.

The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.

Millan MJ, Marin P, Kamal M, Jockers R, Chanrion B, Labasque M, Bockaert J, Mannoury la Cour C.

Int J Neuropsychopharmacol. 2011 Jul;14(6):768-83. doi: 10.1017/S1461145710001045. Epub 2010 Oct 15.

PMID:
20946699
19.

Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia.

Werkman TR, Glennon JC, Wadman WJ, McCreary AC.

CNS Neurol Disord Drug Targets. 2006 Feb;5(1):3-23. Review.

PMID:
16613551
20.

Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.

Bubar MJ, Cunningham KA.

Prog Brain Res. 2008;172:319-46. doi: 10.1016/S0079-6123(08)00916-3. Review.

PMID:
18772040

Supplemental Content

Support Center